Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.55 |
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619560 | 0.85 | MGLL (0.65) | HPGDKMT2A | |
| SCHEMBL16619621 | 0.82 | HTR2B (0.60) | HPGDKDM4EALDH1A1KMT2AHTR2B | |
| SCHEMBL16150341 | 0.82 | FASN (0.63) | HPGDKDM4EALDH1A1KMT2AHTR2B | |
| SCHEMBL17390003 | 0.81 | HTR2B (0.57) | HPGDKDM4EALDH1A1KMT2AHTR2B | |
| SCHEMBL16150702 | 0.81 | CHEK2 (0.56) | HPGDKDM4EALDH1A1KMT2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL16149784 | 0.81 | ATR (0.58) | HPGDKDM4EALDH1A1KMT2AHTR2B | |
| SCHEMBL15154918 | 0.80 | HTR2B (0.60) | HPGDKDM4EALDH1A1KMT2AHTR2B | |
| SCHEMBL17706589 | 0.79 | KDM4E (0.70) | HPGDKDM4EALDH1A1KMT2AHTR2B | |
| SCHEMBL1664216 | 0.77 | KDM4E (0.97) | HPGDKDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL11331533 | 0.76 | KDM4E (0.73) | HPGDKDM4EALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052483-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-08-10 | — | — | EP | claimed |
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-08-04 | — | — | US | claimed |
| WO-2015049651-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | WO | claimed |
| EP-3052483-B1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-02-06 | — | — | EP | disclosed |
| US-9938243-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170369448-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-28 | — | — | US | disclosed |
| US-9809558-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-3052483-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| WO-2015049651-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | ALB, HDGF, VEGFA | HPGD 2162/4885KDM4E 4577/4885ALDH1A1 3017/4885 |
| US-20170369448-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | ALB, HDGF, VEGFA | HPGD 2162/4885KDM4E 4577/4885ALDH1A1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.